Skip to main content

Table 3 Lymphocyte subsets in peripheral blood: cervical cancer versus precancerous lesion

From: Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients

 Cancer (n = 43)Precancerous lesion (n = 13)P value*
Gran %CD453.05 ± 5.294.17 ± 6.170.522
T %MNC57.41 ± 12.7959.58 ± 9.540.575
rdT %T7.30 ± 4.454.83 ± 2.220.067
B %MNC6.05 ± 3.116.48 ± 2.480.644
pDC % MNC0.25 ± 0.130.35 ± 0.160.022#
CD11c + % pDC7.62 ± 5.036.18 ± 1.970.386
Baso % MNC0.98 ± 0.711.19 ± 0.600.334
BDCA1+ mDC % MNC0.38 ± 0.180.65 ± 0.23< 0.001#
BDCA3+ mDC % MNC0.17 ± 0.040.03 ± 0.050.374
Mono %MNC15.56 ± 9.2417.62 ± 8.010.473
CD14+ Mo % MNC14.63 ± 6.9816.98 ± 7.000.359
CD16+ Mo % MNC3.07 ± 2.192.52 ± 1.040.448
CD16+ %Mono15.58 ± 7.8613.36 ± 3.290.020#
NK %MNC16.11 ± 9.3410.90 ± 4.910.060
CD56hi NK % MNC0.33 ± 0.150.29 ± 0.190.508
CD56lo NK % MNC17.26 ± 9.6210.36 ± 5.330.037#
CD56hi %NK2.54 ± 2.053.93 ± 3.030.106
MDSC % CD33hi1.85 ± 3.323.42 ± 7.740.547
DR- %14 + APC0.51 ± 1.550.38 ± 0.950.800
DR- %16 + APC0.88 ± 1.600.44 ± 0.750.404
  1. *Independent t test
  2. #P values with statistical significance were denoted